AbCellera Results Presentation Deck

2020 BUSINESS UPDATE. TECHNOLOGY EXPANSION ACQUISITIONS TO EXPAND THE BREADTH & DEPTH OF OUR TECH STACK Combine any two antibodies to create bispecific antibodies. THI B H OrthoMabTM bispecific engineering platform, coupled with our discovery engine, has the potential to be best-in-class. Source fully human antibodies from rodents. Ab Cellera Trianni next-generation mice are TRIANNI suited for generating antibodies an AbCellera company against some of the toughest problems in the industry. COPYRIGHT ABCELLERA 13

View entire presentation